Advertisement
U.S. markets closed

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
65.88-2.09 (-3.07%)
At close: 04:00PM EDT
66.00 +0.12 (+0.18%)
After hours: 04:04PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close67.97
Open67.63
Bid65.76 x 200
Ask65.99 x 100
Day's Range64.84 - 67.89
52 Week Range45.50 - 76.11
Volume573,953
Avg. Volume750,541
Market Cap6.378B
Beta (5Y Monthly)1.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ITCI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Intra-Cellular Therapies Inc.
    CYTK: Raising target price to $79.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $79.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

    NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the position of President. Mr. Halstead is currently serving as Executive Vice President and General Counsel. In this newly created leadership role, Mr. Halstead will oversee several functions within the Company

  • GlobeNewswire

    Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

    NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences: Leerink Partners Global Biopharma ConferenceTuesday, March 12, 2024 at 10:40 a.m. ET in Miami, FL Jefferies Biotech on the Bay Summit Wednesday, March 13, 2024 in Miami, FL UBS Virtual CNS D

  • GlobeNewswire

    Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

    NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m. ET in Boston, MA. The live and archived webcast can be accessed under "Events